Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 4, 2016, Pages 1033-1043

  Kumar, Abhinav ^a   Bicer, Elif Melis ^a   Morgan, Anna Babin ^a   Pfeffer, Paul E ^a   Monopoli, Marco ^b   Dawson, Kenneth A ^b   Eriksson, Jonny ^c   Edwards, Katarina ^c   Lynham, Steven ^a   Arno, Matthew ^a   Behndig, Annelie F ^d   Blomberg, Anders ^d   Somers, Graham ^e   Hassall, Dave ^e   Dailey, Lea Ann ^a   Forbes, Ben ^a   Mudway, Ian S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UPPSALA UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Nanoparticle; Plasma; Poly(vinyl) acetate; Protein corona; Proteomics; Respiratory tract lining fluid; Silica

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; LININGS; MOLECULAR BIOLOGY; NANOPARTICLES; PLASMAS; SILICA;

DRUG DELIVERY VEHICLES; FUNCTIONAL PROTEINS; HUMAN RESPIRATORY TRACT; INNATE IMMUNITY; PROTEIN CORONAS; PROTEOMICS; RESPIRATORY TRACT; SURFACTANT PROTEIN A;

PROTEINS;

ACETIC ACID DERIVATIVE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; NANOPARTICLE; NAPSIN A; SILICON DIOXIDE; SURFACTANT PROTEIN A; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; NAPSA PROTEIN, HUMAN; PROTEIN CORONA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EPITHELIAL LINING FLUID; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOREGULATION; INNATE IMMUNITY; LIQUID; MALE; NORMAL HUMAN; PROTEOMICS; QUANTITATIVE ANALYSIS; RESPIRATORY SYSTEM; BIOSYNTHESIS; BODY FLUID; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; ISOLATION AND PURIFICATION; METABOLISM;

ADULT; ASPARTIC ACID ENDOPEPTIDASES; BODY FLUIDS; COMPLEMENT C1Q; COMPLEMENT C3; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; NANOPARTICLES; PROTEIN CORONA; PROTEOMICS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; RESPIRATORY SYSTEM; SILICON DIOXIDE;

EID: 84961216142     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.12.369     Document Type: Article

References (66)

1. Walkey C.D., Olsen J.B., Song F., Liu R., Guo H., Olsen D.W.H., et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 2014, 8:2439-2455.
2. Tenzer S., Docter D., Kuharev J., Musyanovych A., Fetz V., Hecht R., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol 2013, 8:772-781.
3. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012, 7:779-786.
4. Mahon E., Salvati A., Baldelli Bombelli F., Lynch I., Dawson K.A. Designing the nanoparticle-biomolecule interface for 'targeting and therapeutic delivery'. J Control Release 2012, 161:164-174.
5. Peng Q., Wei X.-Q., Yang Q., Zhang S., Zhang T., Shao X.-R., et al. Enhanced biostability of nanoparticle-based drug delivery systems by albumin corona. Nanomedicine (Lond) 2015, 10:205-214.
6. Caracciolo G. Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. Nanomedicine 2015, 11:543-557.
7. Behzadi S., Serpooshan V., Sakhtianchi R., Müller B., Landfester K., Crespy D., et al. Protein corona change the drug release profile of nanocarriers: the 'overlooked' factor at the nanobio interface. Colloids Surf B: Biointerfaces 2014, 123:143-149.
8. Sánchez-Moreno P., Buzón P., Boulaiz H., Peula-García J.M., Ortega-Vinuesa J.L., Luque I., et al. Balancing the effect of corona on therapeutic efficacy and macrophage uptake of lipid nanocapsules. Biomaterials 2015, 61:266-278.
9. Health Effects Institute Traffic-related air pollution: a critical review of the literature on emissions, exposure, and health effects 2010.
10. Lugade A.A., Bogner P.N., Thatcher T.H., Sime P.J., Phipps R.P., Thanavala Y. Cigarette smoke exposure exacerbates lung inflammation and compromises immunity to bacterial infection. J Immunol 2014, 192:5226-5235.
11. Kumar A., Dailey L.A., Forbes B. Lost in translation: what is stopping inhaled nanomedicines from realizing their potential?. Ther Deliv 2014, 5:757-761.
12. Rogueda P.G., Traini D. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert Opin Drug Deliv 2007, 4:595-606.
13. Rogueda P.G., Traini D. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opin Drug Deliv 2007, 4:607-620.
14. Kumar A., Forbes B., Mudway I., Bicer E.M., Dailey L.A. What are the biological and therapeutic implications of biomolecule corona formation on the surface of inhaled nanomedicines?. Nanomedicine 2015, 10:343-345.
15. Schleh C., Kreyling W.G., Lehr C.-M. Pulmonary surfactant is indispensable in order to simulate the in vivo situation. Part Fibre Toxicol 2013, 10:6.
16. Monopoli M.P., Walczyk D., Campbell A., Elia G., Lynch I., Bombelli F.B., et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011, 133:2525-2534.
17. Maiorano G., Sabella S., Sorce B., Brunetti V., Malvindi M.A., Cingolani R., et al. Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. ACS Nano 2010, 4:7481-7491.
18. Casals E., Pfaller T., Duschl A., Oostingh G.J., Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 2010, 4:3623-3632.
19. Nel A.E., Mädler L., Velegol D., Xia T., Hoek E.M.V., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557.
20. Brun E., Sicard-Roselli C. Could nanoparticle corona characterization help for biological consequence prediction?. Cancer Nanotechnol 2014, 5:7.
21. Lesniak A., Fenaroli F., Monopoli M.P., Åberg C., Dawson K.A., Salvati A. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano 2012, 6:5845-5857.
22. Salvati A., Pitek A.S., Monopoli M.P., Prapainop K., Bombelli F.B., Hristov D.R., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013, 8:137-143.
23. Wang F., Yu L., Monopoli M.P., Sandin P., Mahon E., Salvati A., et al. The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. Nanomedicine 2013, 9:1159-1168.
24. Nguyen E.V., Gharib S.A., Schnapp L.M., Goodlett D.R. Shotgun MS proteomic analysis of bronchoalveolar lavage fluid in normal subjects. Proteomics Clin Appl 2014, 8:737-747.
25. Kingma P.S., Whitsett J.A. In defense of the lung: surfactant protein A and surfactant protein D. Curr Opin Pharmacol 2006, 6:277-283.
26. Van Lenten B.J., Wagner A.C., Navab M., Anantharamaiah G.M., Hui E.K.-W., Nayak D.P., et al. D-4 F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004, 110:3252-3258.
27. Gorrini M., Lupi A., Iadarola P., Dos Santos C., Rognoni P., Dalzoppo D., et al. SP-A binds alpha1-antitrypsin in vitro and reduces the association rate constant for neutrophil elastase. Respir Res 2005, 6:146.
28. Dobryszycka W. Biological functions of haptoglobin--new pieces to an old puzzle. Eur J Clin Chem Clin Biochem 1997, 35:647-654.
29. Mandal A.K., Zhang Z., Ray R., Choi M.S., Chowdhury B., Pattabiraman N., et al. Uteroglobin represses allergen-induced inflammatory response by blocking PGD2 receptor-mediated functions. J Exp Med 2004, 199:1317-1330.
30. Craig-Barnes H.A., Doumouras B.S., Palaniyar N. Surfactant protein D interacts with alpha2-macroglobulin and increases its innate immune potential. J Biol Chem 2010, 285:13461-13470.
31. Kendall M., Guntern J., Lockyer N.P., Jones F.H., Hutton B.M., Lippmann M., et al. Urban PM2.5 surface chemistry and interactions with bronchoalveolar lavage fluid. Inhal Toxicol 2004, 16(Suppl. 1):115-129.
32. Kendall M., Tetley T.D., Wigzell E., Hutton B., Nieuwenhuijsen M., Luckham P. Lung lining liquid modifies PM(2.5) in favor of particle aggregation: a protective mechanism. Am J Physiol Lung Cell Mol Physiol 2002, 282:L109-L114.
33. Jiménez-Rojo N., Lete M.G., Rojas E., Gil D., Valle M., Alonso A., et al. Lipidic nanovesicles stabilize suspensions of metal oxide nanoparticles. Chem Phys Lipids 2015, 191:84-90.
34. Schleh C., Hohlfeld J.M. Interaction of nanoparticles with the pulmonary surfactant system. Inhal Toxicol 2009, 21(Suppl. 1):97-103.
35. Behndig A.F., Larsson N., Brown J.L., Stenfors N., Helleday R., Duggan S.T., et al. Proinflammatory doses of diesel exhaust in healthy subjects fail to elicit equivalent or augmented airway inflammation in subjects with asthma. Thorax 2011, 66:12-19.
36. Hu Y., Malone J.P., Fagan A.M., Townsend R.R., Holtzman D.M. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 2005, 4:2000-2009.
37. Jones M.-C., Jones S.A., Riffo-Vasquez Y., Spina D., Hoffman E., Morgan A., et al. Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility. J Control Release 2014, 183:94-104.
38. Almgren M., Edwards K., Karlsson G. Cryo transmission electron microscopy of liposomes and related structures. Colloids Surf A Physicochem Eng Asp 2000, 174:3-21.
39. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996, 68:850-858.
40. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74:5383-5392.
41. Callister S.J., Barry R.C., Adkins J.N., Johnson E.T., Qian W.-J., Webb-Robertson B.-J.M., et al. Normalization approaches for removing systematic biases associated with mass spectrometry and label-free proteomics. J Proteome Res 2006, 5:277-286.
42. Napierska D., Thomassen L.C.J., Lison D., Martens J.A., Hoet P.H. The nanosilica hazard: another variable entity. Part Fibre Toxicol 2010, 7:39.
43. Gul M.O., Jones S.A., Dailey L.A., Nacer H., Ma Y., Sadouki F., et al. A poly(vinyl alcohol) nanoparticle platform for kinetic studies of inhaled particles. Inhal Toxicol 2009, 21:631-640.
44. Waisman D., Danino D., Weintraub Z., Schmidt J., Talmon Y. Nanostructure of the aqueous form of lung surfactant of different species visualized by cryo-transmission electron microscopy. Clin Physiol Funct Imaging 2007, 27:375-380.
45. Tahara Y., Fujiyoshi Y. A new method to measure bilayer thickness: cryo-electron microscopy of frozen hydrated liposomes and image simulation. Micron 1994, 25:141-149.
46. Mu X., Zhong Z. Preparation and properties of poly(vinyl alcohol)-stabilized liposomes. Int J Pharm 2006, 318:55-61.
47. Dell'Orco D., Lundqvist M., Oslakovic C., Cedervall T., Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One 2010, 5.
48. Vogler E.A. Protein adsorption in three dimensions. Biomaterials 2012, 33:1201-1237.
49. Kendall M., Hodges N.J., Whitwell H., Tyrrell J., Cangul H. Nanoparticle growth and surface chemistry changes in cell-conditioned culture medium. Philos Trans R Soc Lond B Biol Sci 2015, 370:20140100.
50. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428-437.
51. Pham C.T.N., Mitchell L.M., Huang J.L., Lubniewski C.M., Schall O.F., Killgore J.K., et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem 2011, 286:123-130.
52. Pham C.T.N., Thomas D.G., Beiser J., Mitchell L.M., Huang J.L., Senpan A., et al. Application of a hemolysis assay for analysis of complement activation by perfluorocarbon nanoparticles. Nanomedicine 2014, 10:651-660.
53. Serrano A.G., Pérez-Gil J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem Phys Lipids 2006, 141:105-118.
54. Beck-Broichsitter M., Ruppert C., Schmehl T., Günther A., Seeger W. Biophysical inhibition of pulmonary surfactant function by polymeric nanoparticles: role of surfactant protein B and C. Acta Biomater 2014, 10:4678-4684.
55. Kishore U., Greenhough T.J., Waters P., Shrive A.K., Ghai R., Kamran M.F., et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 2006, 43:1293-1315.
56. Ruge C.A., Kirch J., Cañadas O., Schneider M., Perez-Gil J., Schaefer U.F., et al. Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A. Nanomedicine 2011, 7:690-693.
57. Schulze C., Schaefer U.F., Ruge C.A., Wohlleben W., Lehr C.-M. Interaction of metal oxide nanoparticles with lung surfactant protein A. Eur J Pharm Biopharm 2011, 77:376-383.
58. Oosting R.S., Wright J.R. Characterization of the surfactant protein A receptor: cell and ligand specificity. Am J Physiol 1994, 267:L165-L172.
59. Watford W.T., Smithers M.B., Frank M.M., Wright J.R. Surfactant protein A enhances the phagocytosis of C1q-coated particles by alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2002, 283:L1011-L1022.
60. McKenzie Z., Kendall M., Mackay R.-M., Tetley T.D., Morgan C., Griffiths M., et al. Nanoparticles modulate surfactant protein A and D mediated protection against influenza A infection in vitro. Philos Trans R Soc Lond B Biol Sci 2015, 370.
61. Ledford J.G., Addison K.J., Foster M.W., Que L.G. Eosinophil-associated lung diseases. A cry for surfactant proteins A and D help?. Am J Respir Cell Mol Biol 2014, 51:604-614.
62. Gasser M., Wick P., Clift M.J., Blank F., Diener L., Yan B., et al. Pulmonary surfactant coating of multi-walled carbon nanotubes (MWCNTs) influences their oxidative and pro-inflammatory potential in vitro. Part Fibre Toxicol 2012, 9:17.
63. Choi H.S., Ashitate Y., Lee J.H., Kim S.H., Matsui A., Insin N., et al. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol 2010, 28:1300-1303.
64. Kreyling W.G., Hirn S., Schleh C. Nanoparticles in the lung. Nat Biotechnol 2010, 28:1275-1276.
65. Kah J.C.Y., Chen J., Zubieta A., Hamad-Schifferli K. Exploiting the protein corona around gold nanorods for loading and triggered release. ACS Nano 2012, 6:6730-6740.
66. Shahabi S., Treccani L., Dringen R., Rezwan K. Utilizing the protein corona around silica nanoparticles for dual drug loading and release. Nanoscale 2015, 7:16251-16265.